(Q33383334)

26 July 2017

title

Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer (English)

1 reference

26 July 2017

Tsuneo Shimokawa

1

1 reference

26 July 2017

Masahiko Shibuya

2

1 reference

26 July 2017

Kazuhiro Kitamura

3

1 reference

26 July 2017

Yukio Hosomi

4

1 reference

26 July 2017

Suguru Hibino

5

1 reference

26 July 2017

Tomohiro Ota

6

1 reference

26 July 2017

Mari Iguchi

7

1 reference

26 July 2017

Tatsuru Okamura

8

1 reference

26 July 2017

Akihiko Gemma

9

1 reference

26 July 2017

publication date

20 February 2009

1 reference

International Journal of Clinical Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

14

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

63-69

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-008-0802-2

26 July 2017

exact match

0 references

cites work

A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0802-2

In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0802-2

Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0802-2

Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0802-2

Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0802-2

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-008-0802-2

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Small-cell lung cancer

1 reference

12 December 2020

Treatment of small cell lung cancer

1 reference

12 December 2020

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

1 reference

12 December 2020

Second-line treatment of small-cell lung cancer. The case for systemic chemotherapy.

1 reference

12 December 2020

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

1 reference

12 December 2020

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

1 reference

12 December 2020

In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines

1 reference

12 December 2020

Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group

1 reference

12 December 2020

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group

1 reference

12 December 2020

Hematological aspects of a novel 9-aminoanthracycline, amrubicin

1 reference

12 December 2020

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

12 December 2020

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group

1 reference

12 December 2020

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

1 reference

12 December 2020

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

1 reference

12 December 2020

Small-cell lung cancer

1 reference

12 December 2020

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy

1 reference

12 December 2020

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

12 December 2020

Single-agent gemcitabine in patients with resistant small-cell lung cancer

1 reference

12 December 2020

10.1007/S10147-008-0802-2

Identifiers

DOI

1 reference

26 July 2017

1 reference